Neuraminidase antibodies and H5N1: Geographic-dependent influenza epidemiology could determine cross-protection against emerging strains [3]

PLoS Medicine

Volumn 4, Issue 6, 2007, Pages 1130-1131

  Bermejo Martin, Jesus F ^a   Kelvin, David J ^b,c   Guan, Yi ^d   Chen, Honglin ^d   Perez Breña, Pilar ^e   Casas, Inmaculada ^e   Arranz, Eduardo ^a   De Lejarazu, Raul O ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; SIALIDASE; VIRUS ANTIBODY;

HUMAN; IMMUNE SYSTEM; IMMUNITY; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; LETTER; SEASONAL VARIATION; VIRUS STRAIN; ANIMAL; EPIDEMIC; IMMUNOLOGY; MOUSE; NOTE; ORTHOMYXOVIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 34347206042     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040212     Document Type: Letter

References (2)

1. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, et al. (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4: e59. doi:10.1371/journal.pmed.0040059
2. Tumpey TM, Renshaw M, Clements JD, Katz JM (2001) Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75: 5141-5150.